Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.56 |
| ▸ | FBP1 | P09467 | 2/20 | 0.56 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17028600 | 0.98 | APOBEC3A (0.59) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL2147098 | 0.95 | — | — | |
| SCHEMBL7325816 | 0.75 | APOBEC3A (0.61) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL15007108 | 0.75 | DRD2 (0.33) | PDK1FBP1APOBEC3AAPOBEC3G | |
| SCHEMBL3867320 | 0.73 | PDK1 (0.54) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL171200 | 0.73 | PDK1 (0.54) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL2749715 | 0.73 | PDK1 (0.54) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL12210600 | 0.73 | PDK1 (0.54) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL10965367 | 0.73 | APOBEC3A (0.59) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A | |
| SCHEMBL558522 | 0.73 | APOBEC3A (0.95) | PDK1FBP1APOBEC3AAPOBEC3GADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-06-05 | — | — | US | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4486743-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-01-08 | — | — | EP | disclosed |
| CN-118765280-A | RIP1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7214801-B2 | Condensation reagents and a process for their preparation | LANXESS DEUTSCHLAND GMBH (DE) | 2007-05-08 | — | — | US | disclosed |
| US-7214801-B2 | Condensation reagents and a process for their preparation | LANXESS DEUTSCHLAND GMBH (DE) | 2007-05-08 | — | — | US | disclosed |
| US-7214801-B2 | Condensation reagents and a process for their preparation | LANXESS DEUTSCHLAND GMBH (DE) | 2007-05-08 | — | — | US | disclosed |
| US-7064216-B2 | Condensation reagents and a process for their preparation | BAYER AKTIENGESELLSCHAFT (DE) | 2006-06-20 | — | — | US | disclosed |
| EP-1216997-B1 | 2-bromo/chloro-thiazolium salts and their use as condensation agents | LANXESS DEUTSCHLAND GMBH (DE) | 2006-02-15 | — | — | EP | disclosed |
| US-20050267174-A1 | Condensation reagents and a process for their preparation | RUDOLPH JOACHIM | 2005-12-01 | — | — | US | disclosed |
| US-20020156287-A1 | Condensation reagents and a process for their preparation | LANXESS DEUTSCHLAND GMBH (DE) | 2002-10-24 | — | — | US | disclosed |
| EP-1216997-A2 | 2-bromo/chloro-thiazolium salts and their use as condensation agents | BAYER AG (DE) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267174-A1 | Condensation reagents and a process for their preparation | C9, QPCT, RCC1 | PDK1 2160/4885FBP1 3550/4885APOBEC3A 4156/4885 |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | PDK1 951/4885FBP1 2938/4885APOBEC3A 1982/4885 |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | HRH3, HRH4, HRH1 | PDK1 1536/4885FBP1 4272/4885APOBEC3A 3842/4885 |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | PDK1 649/4885FBP1 378/4885APOBEC3A 4509/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | PDK1 504/4885FBP1 2975/4885APOBEC3A 3476/4885 |
| US-20020156287-A1 | Condensation reagents and a process for their preparation | RCC1, C9, CCNT1 | PDK1 3160/4885FBP1 2018/4885APOBEC3A 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.